In addition to our series of NSCLCs with MET co-alterations, single cases of EGFRM+ NSCLC with concurrent de novo MET-amplification, inherent resistance to EGFR-TKIs, and response to the subsequent dual EGFR/MET blockade by the combination erlotinib/crizotinib have been described [140,141]. This evidence concerns the gene MET and non-small cell lung carcinoma.